Aleksander Slusarczyk
Overview
Explore the profile of Aleksander Slusarczyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garbas K, Zapala L, Slusarczyk A, Piekarczyk H, Piecha T, Radziszewski P
BMC Urol
. 2025 Mar;
25(1):44.
PMID: 40050880
Background: To evaluate and synthesize existing evidence on non-invasive methods for diagnosing detrusor underactivity (DU) in men presenting with lower urinary tract symptoms (LUTS), focusing on their feasibility and diagnostic...
2.
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Slusarczyk A, Soria F, et al.
BJU Int
. 2025 Feb;
PMID: 39967051
Objective: To assess the oncological outcomes of patients with high-risk (HR) and very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette-Guérin (BCG) instillations...
3.
Slusarczyk A, Wolanski R, Milow J, Piekarczyk H, Lipinski P, Zapala P, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062114
Radical cystectomy (RC) remains a mainstay surgical treatment for non-metastatic muscle-invasive and BCG-unresponsive bladder cancer. Various perioperative scoring tools assess comorbidity burden, complication risks, and cancer-specific mortality (CSM) risk. We...
4.
Scilipoti P, Slusarczyk A, de Angelis M, Soria F, Pradere B, Krajewski W, et al.
Eur Urol Oncol
. 2024 Jun;
7(6):1293-1302.
PMID: 38902138
Background And Objective: Intravesical mitomycin C (MMC) instillations are recommended to prevent recurrence of intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC); however, the optimal regimen and dose are uncertain. Our aim was...
5.
Bobrowicz M, Kusowska A, Krawczyk M, Zhylko A, Forcados C, Slusarczyk A, et al.
Oncoimmunology
. 2024 Jun;
13(1):2362454.
PMID: 38846084
Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are...
6.
Garbas K, Zapala L, Slusarczyk A, Piecha T, Gwara P, Zuk-Lapan A, et al.
Int Urol Nephrol
. 2024 May;
56(11):3485-3494.
PMID: 38819576
Purpose: Our study aimed to develop a noninvasive model using a combination of the set of clinical data and uroflowmetry (UFL) to differentiate between detrusor underactivity (DU) and bladder outlet...
7.
Slusarczyk A, Garbas K, Pustula P, Zapala L, Radziszewski P
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730636
The currently available EORTC, CUETO and EAU2021 risk stratifications were originally developed to predict recurrence and progression in non-muscle-invasive bladder cancer (NMIBC). However, they have not been validated to differentiate...
8.
9.
Slusarczyk A, Ismail H, Zapala L, Piecha T, Zapala P, Radziszewski P
Ann Surg Oncol
. 2024 Apr;
31(7):4773-4786.
PMID: 38570378
Background: This study aimed to characterize the urinary and tumor microbiomes in patients with non-muscle-invasive bladder cancer (NMIBC) before and after transurethral resection of the bladder tumor (TURBT). Methods: This...
10.
Zapala P, Slusarczyk A, Zapala L, Borkowski T, Rajwa P, Niemczyk G, et al.
Cent European J Urol
. 2024 Jan;
76(4):293-299.
PMID: 38230322
Introduction: This study aimed to evaluate cancer-specific (CSM) and other-cause mortality (OCM) in elderly patients with prostate cancer treated with radical prostatectomy (RP) and postoperative radiotherapy (RT). Material And Methods:...